US President Donald Trump has launched a new self-branded website, TrumpRx.gov, aimed at helping Americans access prescription drugs at reduced prices by linking consumers directly to pharmaceutical companies’ discount programmes.
Announcing the initiative on Thursday at the White House, Trump said the platform would serve as a central hub for lower-cost medications, including treatments for weight loss and infertility, as part of his broader effort to address rising living costs ahead of the November midterm elections.
“Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers,” Trump said during the event.
He argued that Americans have long paid higher drug prices than consumers in other countries, effectively subsidising global pharmaceutical costs.
According to the president, major drugmakers Eli Lilly and Novo Nordisk have agreed to offer their popular GLP-1 weight-loss medications at significantly reduced prices through the TrumpRx platform.
Novo Nordisk’s Ozempic, which typically costs over $1,000 per month, will be available for $199 monthly, while Eli Lilly’s Wegovy will drop from around $1,300 to the same price point.
The website notes that prices will increase gradually after an initial two-month period.
During the launch event, a woman was introduced as the first user of the TrumpRx platform to obtain a fertility treatment medication at a reduced cost.
Mehmet Oz, a former television personality now serving as administrator of the Centers for Medicare and Medicaid Services, highlighted the potential impact of the price cuts while addressing the audience.
The White House said the website is launching with discounts on more than 40 widely used prescription drugs. Consumers can search for medications on the platform, print discount coupons and present them at participating pharmacies to access the reduced prices.
The TrumpRx initiative follows a series of pricing agreements announced by the administration with leading pharmaceutical companies. These deals include commitments to “Most Favored Nation” pricing, which aligns US drug prices with the lowest rates offered in other developed countries. In return, companies have reportedly received incentives such as relief from tariffs imposed by the administration since Trump returned to office last year.
Trump has also pressured several countries, including the United Kingdom and France, to negotiate pharmaceutical pricing arrangements, at times publicly criticising foreign leaders who opposed the measures.
Although Trump previously downplayed voter concerns over affordability, he has recently made cost-of-living issues a central theme of his messaging as Republicans prepare for closely contested midterm elections. Opinion polls indicate the president is facing low approval ratings, particularly on economic issues, raising concerns within his party about the potential loss of control of Congress.
The president has warned that a Republican defeat in the midterms could expose him to renewed impeachment efforts, adding to the political stakes surrounding his latest policy push.
